Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Boost radiation Clear all
Completed Phase 1 Interventional Results available

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Not yet recruiting Not applicable Interventional

Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing

NCT07787572
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
transcranial alternating current stimulation, sham transcranial alternating current stimulation, Motivational interviewing (MI)
Device · Behavioral
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biology of Osteosarcoma (BOOST) Registry and Biobank

NCT03225872
View directory record Official record
Conditions
Osteosarcoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years and older
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 20, 2026, 4:38 PM EDT
Recruiting Phase 2 Interventional

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

NCT06129747
View directory record Official record
Conditions
Breast Cancer, Tumor, Breast
Interventions
Radiation Therapy
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Withdrawn Not applicable Interventional

Phase I Study MR-guided SBRT to PCa

NCT03935308
View directory record Official record
Conditions
Low or Intermediate Risk Prostate Cancer
Interventions
MR guided Linear Accelerator
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 20, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 20, 2026, 4:38 PM EDT
Terminated Phase 1 Interventional

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

NCT00630890
View directory record Official record
Conditions
Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions
External beam radiation and Cyberknife radiosurgery boost and capecitabine
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

NCT03366844
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, RT Boost
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00020709
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, gefitinib, radiation therapy, placebo
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 20, 2026, 4:38 PM EDT
Recruiting Phase 1 Interventional

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

NCT05077137
View directory record Official record
Conditions
Melanoma
Interventions
Tetanus Diptheria Vaccine, Polio Boost Immunization
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Group Study to Evaluate the Effects of an Eyelash Serum on Improving Eyelash Growth

NCT06125730
View directory record Official record
Conditions
Eyelash Growth
Interventions
DIME Beauty Eyelash Boost Serum
Other
Lead sponsor
Dime Beauty Co.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)

NCT03484364
View directory record Official record
Conditions
Hypertension
Interventions
ENACTS
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 20, 2026, 4:38 PM EDT
Terminated Phase 4 Interventional

BNP Therapy Observation Unit Outcomes STudy (BOOST)

NCT00453453
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nesiritide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Sep 20, 2026, 4:38 PM EDT
Withdrawn Phase 2 Interventional

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

NCT05445882
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
Bintrafusp alfa, N-803, BN-Brachyury
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 20, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

NCT06395506
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Muscle Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 20, 2026, 4:38 PM EDT
Withdrawn Phase 2 Interventional

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NCT03628144
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA
Interventions
Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)
Dietary Supplement · Radiation · Drug + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 20, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight

NCT07363616
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Risk Factors
Interventions
Mediterranean eating style, Physical activity, Mindful Eating, Body Appreciation, Enjoyable Exercise
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Active, not recruiting Not applicable Interventional

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

NCT07115901
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Lump sum, Monthly installments, Choice
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00265941
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
363
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 255 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 20, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes

NCT07176988
View directory record Official record
Conditions
Dysphonia, Primary Muscle Tension Dysphonia (MTD)
Interventions
Hierarchical method, Non Hierarchical method
Other
Lead sponsor
Emory University
Other
Eligibility
16 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Diabetes Prevention Program Outcomes Study

NCT00038727
View directory record Official record
Conditions
Diabetes Mellitus, Cancer, CVD
Interventions
DPPOS Group Lifestyle, Metformin, DPPOS Boost Lifestyle, Intensive Lifestyle Group Session
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years and older
Enrollment
2,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 20, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

NCT05182112
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Whole liver irradiation (WLI), Gemcitabine and Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 20, 2026, 4:38 PM EDT